Cargando…

562. Tocilizumab for the Treatment of Severe COVID-19: A Retrospective, Multi-Center, Case-Matched Series

BACKGROUND: At the time of this writing, there is no FDA approved medication for the treatment of COVID-19. One medication currently under investigation for COVID-19 treatment is tocilizumab, an interleukin-6 (IL-6) inhibitor. It has been shown there are increased levels of cytokines including IL-6...

Descripción completa

Detalles Bibliográficos
Autores principales:	Norman, Sarah, Jones, Sara, Reeves, David, Cheatham, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776610/ http://dx.doi.org/10.1093/ofid/ofaa439.756

Ejemplares similares

562. Tocilizumab Use in the Second Trimester Pregnant Patients with Severe Covid-19 Pneumonia and their Maternal and Fetal Outcomes: Two Case Reports
por: iqbal, Fatima, et al.
Publicado: (2021)

554. Early Clinical Outcomes with Tocilizumab for Covid-19: A Two-Center Retrospective Study
por: Smoke, Steven, et al.
Publicado: (2020)

139. Impact of Pharmacist Driven Outpatient Fluoroquinolone Stewardship Initiative in Community Based Setting
por: Norman, Sarah, et al.
Publicado: (2020)

551. Remdesivir and Tocilizumab for the Treatment of Severe COVID-19 in a Community Hospital: A Retrospective Cohort Study
por: Rodriguez-Nava, Guillermo, et al.
Publicado: (2021)

553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19
por: Leonard, Michael, et al.
Publicado: (2020)

539. Impact of Corticosteroids when Combined with Tocilizumab or Remdesivir for the Treatment of Severe SARS-CoV-2
por: Rosati, Michael, et al.
Publicado: (2021)

563. Tocilizumab in the Treatment of Critical COVID-19 Pneumonia
por: Fisher, Matthew, et al.
Publicado: (2020)

2687. Extended Infusions of Piperacillin/Tazobactam vs. Cefepime for Empiric Treatment of Neutropenic Fever
por: Norman, Sarah, et al.
Publicado: (2019)

Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls
por: Mert, Ali, et al.
Publicado: (2021)

566. Tocilizumab: A Friend or a Foe in COVID-19 Management?
por: Hernandez, Jarelys M, et al.
Publicado: (2020)

342. Secondary Infections following Tocilizumab for Treatment of COVID-19 Pneumonia
por: Warner, Adam, et al.
Publicado: (2021)

517. Subcutaneous Sarilumab for the Treatment of Hospitalized patients with Moderate to Severe COVID19 Disease: A Pragmatic, Embedded, Multi-Center Randomized Clinical Trial
por: Branch-Elliman, Westyn, et al.
Publicado: (2021)

564. Tocilizumab Induces Rapid, Sustained Improvement of Inflammatory Markers in COVID-19
por: Colgrove, Robert, et al.
Publicado: (2020)

565. Tocilizumab Use in COVID-19: Act(emra) to Inhibit Intubation and Decompensation
por: Willner, Debra M, et al.
Publicado: (2020)

509. A Comparison of Tocilizumab and Baricitinib for Hospitalized Patients with Severe COVID-19
por: Aytoda, Priyanka, et al.
Publicado: (2023)

400. Secondary Infections in COVID-19 Patients Receiving Tocilizumab in a Community Hospital
por: Usiak, Shauna, et al.
Publicado: (2020)

304. Impact of Antibiotic Prophylaxis Prior to Treatment with Steroids and Tocilizumab in COVID-19 Patients
por: de Novales, Francisco Javier Membrillo, et al.
Publicado: (2021)

341. Evaluation of Antimicrobial Use and Prescribing Patterns During the COVID-19 Pandemic in Patients Receiving Tocilizumab
por: Barsoum, Barbara, et al.
Publicado: (2021)

550. Clinical impact of Tocilizumab therapy in SARS-CoV-2 respiratory infections in ICU and non-ICU patients
por: Vyas, Nikunj M, et al.
Publicado: (2020)

P1413: DOES TOCILIZUMAB INCREASE THE RISK OF INFECTIONS IN PATIENTS UNDERGOING CAR-T THERAPY?
por: Greenhalgh, Sophie, et al.
Publicado: (2023)

Tocilizumab for juvenile idiopathic arthritis: a single-center case series
por: Yazılıtaş, Fatma, et al.
Publicado: (2020)

562. Reducing MRSA Bacteremia in Adult Patients through MRSA Decolonization Bundle
por: Goldman, Erin, et al.
Publicado: (2019)

282. Risk Factors for Mortality in Severe COVID-19 Patients Admitted to the Intensive Care Unit: A Retrospective Single-Center Study in Saudi Arabia
por: Khattab, Sherif, et al.
Publicado: (2021)

69: COMPARING THE OUTCOMES OF GIVING TOCILIZUMAB THEN HEMOPERFUSION, HEMOPERFUSION THEN TOCILIZUMAB, AND NO INTERVENTION IN CRITICAL SARS-COV-2 PNEUMONIA PATIENTS IN MAKATI MEDICAL CENTER
por: Macatangay, M.V.R., et al.
Publicado: (2022)

534. The Use of Tocilizumab and Remdesivir in SARS- CoV-2 Patients in El Paso Texas: A Longitudinal Comparative Observational Study
por: Almaghlouth, Nouf K, et al.
Publicado: (2021)

297. Infectious Complications Associated with Tocilizumab Use in Patients Infected with SARS-CoV-2 at a Mid-Atlantic Hospital Consortium
por: Kent, Kristen R, et al.
Publicado: (2021)

Longitudinal immunomonitoring following Tocilizumab in rheumatoid arthritis
por: Pers, Yves-Marie, et al.
Publicado: (2011)

713. Coccidioidal Meningitis Among Children: A Case Series and Single Center Experience In Central California
por: Naeem, Fouzia, et al.
Publicado: (2021)

1158. Pediatric Group A Streptococcal Peritonitis: A Single-Center Eleven Patient Case Series
por: Pershing, Nicole L, et al.
Publicado: (2021)

314. A Retrospective Review of Dalbavancin Utilization at an Academic Medical Center
por: Napoli, Emma, et al.
Publicado: (2020)

682. Is There a Role for the Early Use of Tocilizumab and Interleukin-6 Levels in the Management of SARS-CoV-2 Patients with Early Respiratory Failure?
por: Antony, Suresh J, et al.
Publicado: (2020)

2089. Effect of the Duke Antimicrobial Stewardship Outreach Network (DASON): A Multi-Center Time Series Analysis
por: Yarrington, Michael E, et al.
Publicado: (2019)

261. A Single-Center Case Series of Methicillin-Resistant S. aureus Bacteremia with Elevated Minimal Inhibitory Concentrations to Vancomycin
por: Mills, Alexandra, et al.
Publicado: (2020)

562. Management and Outcomes of Patients With Acute HIV Infection in an Expanded Testing and Linkage to Care Program
por: McNulty, Moira C, et al.
Publicado: (2018)

2440. Weight-Adjusted Piperacillin–Tazobactam (PIP/TAZ) Therapy in Obese Patients vs. Optimized Doses in Non-obese Patients: A Retrospective Cohort Study
por: Moore, Sarah, et al.
Publicado: (2018)

392. Predictors of Mortality in Hospitalized Patients with COVID-19; A Single Centered Retrospective Analysis
por: Harmouch, Farah N, et al.
Publicado: (2020)

700. Ampicillin-Ceftriaxone Versus Ampicillin-Gentamicin for Definitive Therapy of Enterococcus faecalis Infective Endocarditis: A Propensity Score-Matched,Retrospective Cohort Analysis
por: Shah, Niyati H, et al.
Publicado: (2020)

Tocilizumab in patients with severe COVID-19: a retrospective cohort study
por: Guaraldi, Giovanni, et al.
Publicado: (2020)

315. A Multi-center Study to Describe Obese Pediatric Patients with COVID-19 Across the United States
por: Hammoud, Roukaya Al, et al.
Publicado: (2021)

P562: CAPILLARY BLOOD SAMPLING ALLOWS FEASIBLE METHOD FOR VENETOCLAX CONCENTRATION MEASUREMENT IN AN ACADEMIC MULTICENTER CLINICAL TRIAL CONTEXT
por: Kytölä, Sari, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p69t4g7fa2ishtnjlminnc5fpv